United Therapeutics (NASDAQ:UTHR) CEO Sells $1,778,800.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 4,000 shares of the company’s stock in a transaction on Friday, October 10th. The shares were sold at an average price of $444.70, for a total value of $1,778,800.00. Following the completion of the transaction, the chief executive officer directly owned 130 shares in the company, valued at approximately $57,811. This represents a 96.85% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

United Therapeutics Stock Performance

UTHR opened at $440.00 on Monday. The stock has a fifty day moving average of $372.27 and a 200-day moving average of $323.78. The company has a market capitalization of $19.85 billion, a P/E ratio of 17.17, a P/E/G ratio of 4.82 and a beta of 0.66. United Therapeutics Corporation has a fifty-two week low of $266.98 and a fifty-two week high of $459.48.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 EPS for the quarter, missing analysts’ consensus estimates of $6.80 by ($0.39). United Therapeutics had a return on equity of 18.73% and a net margin of 40.36%.The business had revenue of $798.60 million for the quarter, compared to the consensus estimate of $802.13 million. During the same period in the prior year, the business posted $5.85 earnings per share. United Therapeutics’s revenue was up 11.7% compared to the same quarter last year. On average, equities research analysts predict that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on UTHR shares. Wells Fargo & Company lifted their price target on shares of United Therapeutics from $295.00 to $414.00 and gave the company an “equal weight” rating in a research report on Wednesday, September 3rd. Oppenheimer raised their price objective on United Therapeutics from $510.00 to $575.00 and gave the stock an “outperform” rating in a research note on Friday, September 5th. Cantor Fitzgerald upped their target price on United Therapeutics from $405.00 to $525.00 and gave the company an “overweight” rating in a research report on Wednesday, September 10th. Morgan Stanley increased their target price on United Therapeutics from $328.00 to $435.00 and gave the stock an “equal weight” rating in a report on Friday. Finally, Royal Bank Of Canada began coverage on United Therapeutics in a research note on Friday, September 26th. They issued an “outperform” rating and a $569.00 price target for the company. Ten investment analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $457.21.

Hedge Funds Weigh In On United Therapeutics

Institutional investors have recently modified their holdings of the business. XTX Topco Ltd bought a new position in United Therapeutics in the first quarter valued at about $313,000. Allianz Asset Management GmbH lifted its holdings in shares of United Therapeutics by 96.9% in the first quarter. Allianz Asset Management GmbH now owns 67,576 shares of the biotechnology company’s stock worth $20,832,000 after acquiring an additional 33,254 shares during the last quarter. LPL Financial LLC boosted its stake in shares of United Therapeutics by 77.3% in the 1st quarter. LPL Financial LLC now owns 25,246 shares of the biotechnology company’s stock valued at $7,783,000 after purchasing an additional 11,007 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of United Therapeutics by 11.4% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,678 shares of the biotechnology company’s stock valued at $1,129,000 after purchasing an additional 376 shares during the last quarter. Finally, Concurrent Investment Advisors LLC acquired a new position in United Therapeutics during the 1st quarter worth approximately $227,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.